124 related articles for article (PubMed ID: 10567003)
1. Neural contribution to the effect of glucagon-like peptide-1-(7-36) amide on arterial blood pressure in rats.
Barragán JM; Eng J; Rodríguez R; Blázquez E
Am J Physiol; 1999 Nov; 277(5):E784-91. PubMed ID: 10567003
[TBL] [Abstract][Full Text] [Related]
2. Interactions of exendin-(9-39) with the effects of glucagon-like peptide-1-(7-36) amide and of exendin-4 on arterial blood pressure and heart rate in rats.
Barragán JM; Rodríguez RE; Eng J; Blázquez E
Regul Pept; 1996 Nov; 67(1):63-8. PubMed ID: 8952007
[TBL] [Abstract][Full Text] [Related]
3. The hepatic vagal reception of intraportal GLP-1 is via receptor different from the pancreatic GLP-1 receptor.
Nishizawa M; Nakabayashi H; Kawai K; Ito T; Kawakami S; Nakagawa A; Niijima A; Uchida K
J Auton Nerv Syst; 2000 Apr; 80(1-2):14-21. PubMed ID: 10742535
[TBL] [Abstract][Full Text] [Related]
4. Changes in arterial blood pressure and heart rate induced by glucagon-like peptide-1-(7-36) amide in rats.
Barragán JM; Rodríguez RE; Blázquez E
Am J Physiol; 1994 Mar; 266(3 Pt 1):E459-66. PubMed ID: 8166268
[TBL] [Abstract][Full Text] [Related]
5. Effects of glucagon-like peptide-1(7-36) amide on neurohypophysial and cardiovascular functions under hypo- or normotensive hypovolaemia in the rat.
Bojanowska E; Stempniak B
J Endocrinol; 2002 Feb; 172(2):303-10. PubMed ID: 11834448
[TBL] [Abstract][Full Text] [Related]
6. Vagal hepatopancreatic reflex effect evoked by intraportal appearance of tGLP-1.
Nakabayashi H; Nishizawa M; Nakagawa A; Takeda R; Niijima A
Am J Physiol; 1996 Nov; 271(5 Pt 1):E808-13. PubMed ID: 8944665
[TBL] [Abstract][Full Text] [Related]
7. Effects of centrally or systemically injected glucagon-like peptide-1 (7-36) amide on release of neurohypophysial hormones and blood pressure in the rat.
Bojanowska E; Stempniak B
Regul Pept; 2000 Jul; 91(1-3):75-81. PubMed ID: 10967203
[TBL] [Abstract][Full Text] [Related]
8. Repeated intracerebroventricular administration of glucagon-like peptide-1-(7-36) amide or exendin-(9-39) alters body weight in the rat.
Meeran K; O'Shea D; Edwards CM; Turton MD; Heath MM; Gunn I; Abusnana S; Rossi M; Small CJ; Goldstone AP; Taylor GM; Sunter D; Steere J; Choi SJ; Ghatei MA; Bloom SR
Endocrinology; 1999 Jan; 140(1):244-50. PubMed ID: 9886831
[TBL] [Abstract][Full Text] [Related]
9. Peripheral versus central effects of glucagon-like peptide-1 receptor agonists on satiety and body weight loss in Zucker obese rats.
Rodriquez de Fonseca F; Navarro M; Alvarez E; Roncero I; Chowen JA; Maestre O; Gómez R; Muñoz RM; Eng J; Blázquez E
Metabolism; 2000 Jun; 49(6):709-17. PubMed ID: 10877194
[TBL] [Abstract][Full Text] [Related]
10. The hepatic vagal nerve is receptive to incretin hormone glucagon-like peptide-1, but not to glucose-dependent insulinotropic polypeptide, in the portal vein.
Nishizawa M; Nakabayashi H; Uchida K; Nakagawa A; Niijima A
J Auton Nerv Syst; 1996 Nov; 61(2):149-54. PubMed ID: 8946334
[TBL] [Abstract][Full Text] [Related]
11. Mechanisms involved in glucagon-like peptide-1 (7-36) amide action on the rat hypothalamo-neurohypophysial system.
Bojanowska E; Stempniak B
Neuroendocrinology; 2003 Feb; 77(2):119-24. PubMed ID: 12624533
[TBL] [Abstract][Full Text] [Related]
12. Effects of intracerebroventricularly injected glucagon-like peptide-1 on cardiovascular parameters; role of central cholinergic system and vasopressin.
Isbil-Buyukcoskun N; Gulec G
Regul Pept; 2004 Apr; 118(1-2):33-8. PubMed ID: 14759554
[TBL] [Abstract][Full Text] [Related]
13. Effects of glucagon and glucagon-like peptide-1-(7-36) amide on C cells from rat thyroid and medullary thyroid carcinoma CA-77 cell line.
Crespel A; De Boisvilliers F; Gros L; Kervran A
Endocrinology; 1996 Sep; 137(9):3674-80. PubMed ID: 8756532
[TBL] [Abstract][Full Text] [Related]
14. tGLP-1 and release of vasopressin and oxytocin from the isolated rat hypothalamo-neurohypophysial system: effects of a tGLP-1 receptor agonist and antagonist.
Bojanowska E; Stempniak B
J Physiol Pharmacol; 2001 Dec; 52(4 Pt 2):781-93. PubMed ID: 11785773
[TBL] [Abstract][Full Text] [Related]
15. Energy expenditure by intravenous administration of glucagon-like peptide-1 mediated by the lower brainstem and sympathoadrenal system.
Osaka T; Endo M; Yamakawa M; Inoue S
Peptides; 2005 Sep; 26(9):1623-31. PubMed ID: 16112402
[TBL] [Abstract][Full Text] [Related]
16. N-terminally modified glucagon-like peptide-1(7-36) amide exhibits resistance to enzymatic degradation while maintaining its antihyperglycaemic activity in vivo.
O'Harte FP; Mooney MH; Lawlor A; Flatt PR
Biochim Biophys Acta; 2000 Mar; 1474(1):13-22. PubMed ID: 10699485
[TBL] [Abstract][Full Text] [Related]
17. Receptor-mediated activation of gastric vagal afferents by glucagon-like peptide-1 in the rat.
Bucinskaite V; Tolessa T; Pedersen J; Rydqvist B; Zerihun L; Holst JJ; Hellström PM
Neurogastroenterol Motil; 2009 Sep; 21(9):978-e78. PubMed ID: 19453518
[TBL] [Abstract][Full Text] [Related]
18. Enhancement of reflex vagal bradycardia following intracerebroventricular administration of methysergide in cats.
Tadepalli AS; Ho KW; Buckley JP
Eur J Pharmacol; 1979 Oct; 59(1-2):85-93. PubMed ID: 510402
[TBL] [Abstract][Full Text] [Related]
19. Glucagon acts through its own receptors in the presence of functional glucagon-like peptide-1 receptors on hamster insulinoma.
Marie JC; Boissard C; Skoglund G; Rosselin G; Breant B
Endocrinology; 1996 Oct; 137(10):4108-14. PubMed ID: 8828464
[TBL] [Abstract][Full Text] [Related]
20. Central administration of GLP-1-(7-36) amide inhibits food and water intake in rats.
Tang-Christensen M; Larsen PJ; Göke R; Fink-Jensen A; Jessop DS; Møller M; Sheikh SP
Am J Physiol; 1996 Oct; 271(4 Pt 2):R848-56. PubMed ID: 8897973
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
